| Company Name: |
Pharmacodia (Beijing) Co.,Ltd
|
| Tel: |
+86-400-851-9921 |
| Email: |
sales@pharmacodia.com |
| Products Intro: |
Product Name:Conivaptan impurity
Purity:>95% HPLC Package:10mg-100mg
|
| Company Name: |
SHENZHEN PHYSTANDARD BIO-TECH CO.,LTD
|
| Tel: |
0755-0755-0755-83725350 13380397412 |
| Email: |
3001280422@qq.com |
| Products Intro: |
Product Name:Conivaptan impurity
CAS:1129433-63-1
Purity:99% HPLC Package:10mg;25mg;50mg;100mg
|
| Company Name: |
Shanghai isotope chemical co.,ltd
|
| Tel: |
021-021-51600108 13062666369 |
| Email: |
sales@chinaisotope.com |
| Products Intro: |
Product Name:Conivaptan-d4
CAS:1129433-63-1
Purity:1mg Package:1mg Remarks:RMCC56018-1mg
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Conivaptan-d4
CAS:1129433-63-1
Purity:>95% Package:500μg;1mg
|
| Company Name: |
Hubei Moco Chemical Co., Ltd.
|
| Tel: |
18627753421 18627756402 |
| Email: |
3001009495@qq.com |
| Products Intro: |
Product Name:Conivaptan impurity
CAS:1129433-63-1
Purity:95%+hplc Package:5mg/;15mg/;25mg/
|
|
| | Conivaptan impurity Basic information |
| Product Name: | Conivaptan impurity | | Synonyms: | Conivaptan-d4;N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl-d4]-[1,1'-biphenyl]-2-carboxamide | | CAS: | 1129433-63-1 | | MF: | C32H26N4O2 | | MW: | 498.59 | | EINECS: | | | Product Categories: | | | Mol File: | 1129433-63-1.mol |  |
| | Conivaptan impurity Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: soluble | | form | A solid |
| | Conivaptan impurity Usage And Synthesis |
| Biological Activity | Conivaptan-d4 is intended for use as an internal standard for the quantification of conivaptan by GC- or LC-MS. Conivaptan is an antagonist of the arginine vasopressin (AVP) receptors V1A and V2 (Kis = 0.48 and 3.04 nM for rat liver V1A and kidney V2, respectively).1 It also competitively inhibits oxytocin binding to rat uterine oxytocin receptors (Ki = 44 nM) but has no effect on AVP binding to anterior pituitary V1B receptors at concentrations up to 100 μM in a radioligand binding assay. Conivaptan suppresses AVP-induced increases in intracellular calcium in vascular smooth muscle cells (VSMCs) in vitro and the pressor response in pithed rats. Conivaptan (0.01-0.3 mg/kg, i.v.) increases urine output and decreases urine osmolality in dehydrated conscious rats in a dose-dependent manner. It also reduces brain edema and blood-brain barrier disruption in a mouse experimental stroke model.2 | | References | 1.Tahara, A., Tomura, Y., Wada, K.-I., et al.Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivoJ. Pharmacol. Exp. Ther.282(1)301-308(1997)
2.Zeynalov, E., Jones, S.M., Seo, J.W., et al.Arginine-vasopressin receptor blocker conivaptan reduces brain edema and blood-brain barrier disruption after experimental stroke in micePLoS One10(8)e0136121(2015) |
| | Conivaptan impurity Preparation Products And Raw materials |
|